RxDoctor Payments Data

Sabrina Trammel, DO

Hospice and Palliative Medicine · Southampton, NYNPI 1679935092

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 23 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $207 and has fallen 92.6% since, to $15 in 2025.

$505in general payments, 2019–2025

Across 23 payments — averaging $21.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$70
  • AbbVie$67
  • Medtronic$61
  • Currax Pharmaceuticals LLC$61
  • Kyowa Kirin, Inc.$43
  • Shield Therapeutics Inc$42
  • plus $161 from 6 others

What the payments were for

  • Food & beverage$505100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$505 in reported general payments places this provider in the 80th percentile of 133 hospice and palliative medicine providers in New York.

See all hospice and palliative medicine providers in New York

Medicare billing

Part B allowed, 2024
$65,069
Medicare patients
140
Services billed
583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin17$19,058
EliquisApixaban11$12,292
Levothyroxine Sodium76$2,008
Metoprolol Succinate47$929
Atorvastatin Calcium76$628
Gabapentin29$491
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide14$404
Simvastatin39$379
Losartan Potassium38$365
Pantoprazole Sodium26$307
Lisinopril42$284
Rosuvastatin Calcium24$282
Omeprazole30$249
Amlodipine Besylate40$232
Escitalopram Oxalate20$221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$12,29211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 133 hospice and palliative medicine providers in New York.

Other hospice and palliative medicine in Southampton

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →